HOOKIPA Pharma (HOOK) said late Wednesday that it would reduce its workforce by about 80% as part of its restructuring plan.
The company said it expects to begin the restructuring plan in Q4 and substantially complete it by the end of the first half of 2025.
As part of its restructuring plan, the company will pause clinical development of its eseba-vec program for HPV16-positive head and neck cancers, including the early termination of a phase 1/2 trial, despite no issues with efficacy or safety.
Additionally, Hookipa said it also prioritize its HB-700 program for KRAS mutant cancers, which received FDA clearance in April 2024.
The company will continue enrolling patients in its HB-500 HIV program and supporting its HB-400 Hepatitis B program, both developed in partnership with Gilead Sciences.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。